Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Brummelman, Pauline; Koerts, Janneke; Dullaart, Robin P. F.; van den Berg, Gerrit; Tucha, Oliver; Wolffenbuttel, Bruce H. R.; van Beek, Andre P. (2012)
Languages: English
Types: Article
Background In untreated acromegaly patients, decreased cognitive functioning is reported to be associated with the degree of growth hormone (GH) and IGF-1 excess. Whether previous GH excess or current medical treatment for acromegaly specifically affects cognition remains unclear. The aim of this study was to compare cognitive functioning of patients who are treated for acromegaly with patients with non-functioning pituitary adenomas (NFA). In addition, we assessed the influence of prolonged medical treatment after initial transsphenoidal surgery on cognition. Design In this cross-sectional study, 74 patients participated, who were treated for acromegaly (n = 50; median [interquartile range] age: 53 [4565] years) or NFA (n = 24; age: 63 [5970] years). The NFA patients were selected for a high likelihood of normal GH secretion based on an IGF-1 z-score within the normal range (> -2) and zero or one axis substituted. Of the acromegaly patients, 28 had achieved remission, while 22 were biochemically controlled with long-acting somatostatin analogues and/or pegvisomant. Memory and executive functioning were assessed by the 15 Words Test and the Ruff Figural Fluency Test, and reported as z-scores. Results The total patient group scored significantly poorer than the reference population on memory and executive functioning (P <0.001). However, cognitive test performance was not significantly different between acromegaly patients with a persistent disease, acromegaly patients in remission and NFA patients. Conclusion The total patient group scored worse compared with reference populations. We found no association between previous GH excess and cognition. In addition, current medical treatment for GH excess in acromegaly was not related to memory and executive functioning.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Van Dam PS, Aleman A. Insulin-like growth factor-I, cognition and brain ageing. Eur J Pharmacol 2004;490:87-95.
    • 2 Sathiavageeswaran M, Burman P, Lawrence D, Harris AG, Falleti MG, Maruff P. Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12- month study. Eur J Endocrinol 2007;156:439-47.
    • 3 Oertel H, Schneider HJ, Stalla K, Holsboer F, Zihl J. The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism. Psychoneuroendocrinology 2004;29:839-50.
    • 4 Faletti MG, Maruff P, Burman P, Harris A. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta analysis of the current literature. Psychoneuroendocrinology 2006;31:681-91.
    • 5 Leon-Carrion J, Martin-Rodriguez JF, Madrazo-Atutxa A, Soto-Moreno A, Venegas-Moreno A, Torres-Vela E et al. Evidence of cognitive and neurophysiological impairment in patients with untreated naive acromegaly. J Clin Endocrinol Metab 2010;95:4367-79.
    • 6 Van den Berg E, Kloppenburg RP, Kessels RP, Kappelle LJ, Biesels GJ. Type II diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta 2009;1792:470-81.
    • 7 Sievers C, Sa¨mann PG, Pfister H, Dimopoulou C, Czisch M, Roemmler J et al. Cognitive function in acromegaly: description and brain volumetric correlates. Pituitary 2012;15:350-7
    • 8 Tiemensma J, Biermasz NR, Van der Mast RC, Wassenaar MJE, Middelkoop HAM, Pereira AM et al. Increased psychopathology and maladaptive personality traits, but normal cognitive functioning in patients after long term cure of acromegaly. J Clin Endocrinol Metab 2010;95:E392-402.
    • 9 Biermasz NR, Pereira AM, Fro¨ lich M, Romijn JA, Veldhuis JD, Roelfsema F. Ocreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. Am J Physiol Endocrinol Metab 2004;286:E25-30.
    • 10 Neggers SJ, Kopchick JJ, Jørgensen JO, van der Lely AJ. Hypothesis: extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol 2011;164:11-6.
    • 11 Brummelman P, Sattler MG, Meiners LC, Elderson MF, Dullaart RP, Van den Berg G et al. Cognitive performance after postoperative pituitary radiotherapy: a dosimetric study of the hippocampus and the prefrontal cortex. Eur J Endocrinol 2011;166:171-9.
    • 12 Brummelman P, Elderson MF, Dullaart RPF, Van den Berg ACM, Timmer CA, Van den Berg G et al. Cognitive functioning in patients treated for nonfunctioning pituitary macroadenoma and the effects of pituitary radiotherapy. Clin Endocrinol 2011;74:481-7.
    • 13 Van Beek AP, van den Bergh AC, van den Berg LM, van den Berg G, Keers JC, Langendijk JA et al. Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctioning pituitary adenoma. Int J Radiat Oncol Biol Phys 2007;68:986-91.
    • 14 Van der Elst W, Van Boxtel MPJ, Van Breukelen GJP, Jolles J. Rey's Verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc 2005;11:290-302.
    • 15 Ruff RM, Light RH, Evans RW. The Ruff Figural Fluency Test: a normative study with adults. Dev Neuropsychol 1987;3:37-51.
    • 16 United Nations Educational. Scientific and Cultural Organization. International Standard Classifications of Education ISCED. 2006.
    • 17 Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997;27:363-70.
    • 18 Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis G, Slaets JP. Universal risk factors for multifactorial diseases: LifeLines: a threegeneration population-based study. Eur J Epidemiol 2008;23:67-74.
    • 19 Campbell MJ, Gardner MJ. Calculating confidence intervals for some non-parametric analysis. Br Med J 1988;296:1454-6.
    • 20 Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS. Neuropsychological Assessment, New York: Oxford University Press; 2004.
    • 21 Duncan DB. Multiple range and Multiple F tests. Biometrics 1955;11:1-42.
    • 22 Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
    • 23 Tanriverdi F, Yapislar H, Karaca Z, Unluhizarci K, Suer C, Kelestimur F. Evaluation of cognitive performance using P300 auditory event related potentials (ERPs) in patients with growth hormone (GH) deficiency and acromegaly. Growth Horm IGF Res 2009;19:24-30.
    • 24 Postma MR, Netea-Maier RT, van den Berg G, Homan J, Sluiter WJ, Wagenmakers MA. Quality of life is imaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Eur J Endocrinol 2012;166:585-92.
    • 25 Sonino N, Scarpa E, Paoltta A, Fallo F, Boscaro M. Slow-release Lanreotide Treatment in Acromegaly: effects of Quality of Life. Psychother Psychosom 1999;68:165-7.
    • 26 Ruchala M, Stangierska I, Gurgul E, Stangierski A, Fajfer J, Sowinski J. The effect of ocreotide treatment on somatic and psychological symptoms of acromegaly. Neuro Endocrinol Lett 2010;31:265-9.
    • 27 Maor Y, Olmer L, Mozes B. The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients - the role of depression. Mult Scler 2001;7:131-5.
    • 28 Middleton LS, Denney DR, Lynch SG, Parmenter B. The relationship between perceived and objective cognitive functioning in multiple sclerosis. Arch Clin Neuropsychol 2006;21:487-94.
    • 29 Sawrie SM, Martin RC, Kuzniecky R, Faught E, Morawetz R, Jamil F. Subjective versus objective memory change after temporal lobe epilepsy surgery. Neurology 1999;53:1511-7.
    • ª 2012 The Authors. European Journal of Clinical Investigation ª 2012 Stichting European Society for Clinical Investigation Journal Foundation
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from